Advertisement

Journal of Neurology

, Volume 255, Supplement 6, pp 36–42 | Cite as

Corticosteroids and plasma exchange in multiple sclerosis

  • Hayretin TumaniEmail author
Article

Abstract

Corticosteroids (CS) remain a mainstay of treatment for relapses in multiple sclerosis (MS) and optic neuritis. Currently, there is not enough evidence that long-term corticosteroid treatment delays progression of long-term disability in patients with MS. Likewise, it is unclear whether there are, in fact, true differences among the various CS agents, doses, and their applications in specific pulse and tapering regimens.

In some patients suffering from severe steroid-resistant relapses, the clinical response to CS treatment may be insufficient. Such patients may obtain clinical benefit from subsequent plasma exchange (PE). PE is increasingly considered as an individual treatment decision in patients with severe relapses not properly responding to CS. Because of the lack of appropriate studies, PE is not recommended as a permanent disease-modifying strategy in MS patients.

Key words

steroid, corticosteroid plasma exchange plasmapheresis multiple sclerosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anonymous (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 337:441–446Google Scholar
  2. 2.
    Alam SM, Kyriakides T, Lawden M, Newman PK (1993) Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 56:1219–1220PubMedCrossRefGoogle Scholar
  3. 3.
    Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, Francis DA, Perkin GD, Rudge P, Swash M, Katifi H, Farmer S, Frankel J (1997) Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349:902–906PubMedCrossRefGoogle Scholar
  4. 4.
    Beck RW (1995) The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol 113:136–137PubMedGoogle Scholar
  5. 5.
    Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326:581–588PubMedGoogle Scholar
  6. 6.
    Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C (2008) Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev:CD006264Google Scholar
  7. 7.
    Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H (2008) Avonex Combination Trial in relapsing – remitting MS: rationale, design and baseline data. Mult Scler 14:370–382PubMedCrossRefGoogle Scholar
  8. 8.
    Compston DA, Milligan NM, Hughes PJ, Gibbs J, McBroom V, Morgan BP, Campbell AK (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry 50:517–522PubMedCrossRefGoogle Scholar
  9. 9.
    Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L (2000) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev:CD001331Google Scholar
  10. 10.
    Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stuve O (2007) Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 4:618–626PubMedCrossRefGoogle Scholar
  11. 11.
    Gold R, Buttgereit F, Toyka KV (2001) Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117:1–8PubMedCrossRefGoogle Scholar
  12. 12.
    Goodkin DE, Kinkel RP, Weinstock-Guttman B, VanderBrug-Medendorp S, Secic M, Gogol D, Perryman JE, Uccelli MM, Neilley L (1998) A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51:239–245PubMedGoogle Scholar
  13. 13.
    Hellwig K, Lukas C, Brune N, Schimrigk S, Przuntek H, Muller T (2006) Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. ScientificWorldJournal 6:460–465PubMedCrossRefGoogle Scholar
  14. 14.
    Hellwig K, Stein FJ, Przuntek H, Muller T (2004) Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms. BMC Neurol 4:18PubMedCrossRefGoogle Scholar
  15. 15.
    Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366:579–582PubMedCrossRefGoogle Scholar
  16. 16.
    Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG (1985) Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 35:312–319PubMedGoogle Scholar
  17. 17.
    Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC (2006) Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 63:930–935PubMedCrossRefGoogle Scholar
  18. 18.
    Linker RA, Chan A, Sommer M, Koziolek M, Muller GA, Paulus W, Gold R (2007) Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J Neurol 254:1288–1289PubMedCrossRefGoogle Scholar
  19. 19.
    Milligan NM, Newcombe R, Compston DA (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 50:511–516PubMedCrossRefGoogle Scholar
  20. 20.
    Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM (2004) The bio-availability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63:1079–1080PubMedGoogle Scholar
  21. 21.
    Oliveri RL, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F, Fera F, Gambardella A, Zappia M, Pardatscher K, Quattrone A (1998) Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 50:1833–1836PubMedGoogle Scholar
  22. 22.
    Rieckmann P (2006) Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006). Nervenarzt 77:1506–1518PubMedCrossRefGoogle Scholar
  23. 23.
    Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R (2004) Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 63:1081–1083PubMedGoogle Scholar
  24. 24.
    Schilling S, Linker RA, Konig FB, Koziolek M, Bahr M, Muller GA, Paulus W, Gartner J, Bruck W, Chan A, Gold R (2006) Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients. Nervenarzt 77:430–438PubMedCrossRefGoogle Scholar
  25. 25.
    Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, Roche S, Perkin GD, Loizou LA, Ferner R, et al. (1989) Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 39:969–971PubMedGoogle Scholar
  26. 26.
    Tischner D, Weishaupt A, van den Brandt J, Ip CW, Kerkau T, Gold R, Reichardt HM (2007) Antigen therapy of experimental autoimmune encephalomyelitis selectively induces apoptosis of pathogenic T cells. J Neuroimmunol 183:146–150PubMedCrossRefGoogle Scholar
  27. 27.
    Tourtellotte WW, Haerer AF (1965) Use of an Oral Corticosteroid in the Treatment of Multiple Sclerosis; a Double-Blind Study. Arch Neurol 12:536–545PubMedGoogle Scholar
  28. 28.
    Weiner HL, Dau PC, Khatri BO, Petajan JH, Birnbaum G, McQuillen MP, Fosburg MT, Feldstein M, Orav EJ (1989) Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 39:1143–1149PubMedGoogle Scholar
  29. 29.
    Weinshenker BG (1999) Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. J Clin Apher 14:144–148PubMedCrossRefGoogle Scholar
  30. 30.
    Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M (2001) Effects of IV methylprednisolone on brain atrophy in relapsingremitting MS. Neurology 57:1239–1247PubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2008

Authors and Affiliations

  1. 1.Dept. of NeurologyUniversity of UlmUlmGermany

Personalised recommendations